Park Medi World Limited Releases Earnings Call Transcript for Q3 FY26
Park Medi World Limited released its Q3 FY26 earnings call transcript. Revenue for Q3 FY26 was ₹410 crore (18% YoY growth), and for nine months FY26 was ₹1218.9 crore (17% YoY growth). EBITDA margin was 24% for Q3 and 26% for nine months. The company plans to add 660 beds in FY26 and targets 5,260 beds by FY28. It expects to be debt-free by end of February.
The announcement includes detailed financial results, future growth plans with significant bed capacity additions, and financial targets, which are material information for investors and will likely impact the company's stock performance.
The company reported strong year-on-year growth in revenue and EBITDA, provided optimistic future projections for bed capacity expansion and financial targets, and indicated plans to become debt-free, all contributing to a positive sentiment.
Park Medi World Limited has disclosed the transcript of its maiden Earnings Conference Call, which was held on January 29, 2026. The call focused on the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025.
During the call, the management highlighted the company's journey since its inception in 2005, emphasizing its growth into the largest private hospital chain in Haryana and the second-largest in North India. The company currently operates 14 multi-specialty hospitals with 3,250 beds, including 870 ICU beds, across Haryana, Punjab, Delhi, and Rajasthan. The growth strategy is centered around a cluster-based expansion and a doctor-led professional management module, supported by investments in advanced medical technology and successful hospital acquisitions.
The financial performance for Q3 FY26 was presented, with revenue from operations at ₹410 crore (INR 4,100 million), marking an 18% year-on-year growth. For the nine months of FY26, revenue stood at ₹1218.9 crore (INR 12,189 million), a 17% increase year-on-year. EBITDA for Q3 FY26 was ₹99.4 crore (INR 994 million) with a 24% margin, and for the nine months, it was ₹317 crore (INR 3,170 million) with a 26% margin. Profit after tax for Q3 FY26 was ₹52.8 crore (INR 528 million), and for the nine months, it was ₹196.8 crore (INR 1,968 million).
Operational metrics showed an average occupancy of 65% across the network, with Average Revenue Per Occupied Bed (ARPOB) increasing to ₹27,406. The company provided future projections, aiming to add 660 beds in FY26, 500 in FY27, and 850 in FY28, bringing the total bed count to approximately 5,260. Future financial targets include maintaining an EBITDA of 27%, PAT of 17%, and annualized ROCE of 21%.
Key discussions also covered the integration of acquisitions, margin trajectory, managing disallowed claims, the impact of CGHS rate increases, the return on investment for robotics, debt levels (expected to be debt-free by end of February), payer mix, and receivable cycles. The company reaffirmed its commitment to affordable healthcare and a strong balance sheet, with plans for significant bed capacity expansion over the next few years.
What to do with a filing like this
Park Medi World Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Park Medi World Limited. Read the original for the full detail.